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Lapatinib (LAP) is an anticancer drug generally used to treat breast and lung cancer. It
exhibits hypersensitivity reactions in addition to dermatological adverse effects and
photosensitivity. Moreover, LAP binds to serum proteins and is readily biotransformed
in humans, giving rise to several metabolites, such as N- and O-dealkylated products
(N-LAP and O-LAP, respectively). In this context, the aim of the present work is to
obtain key information on drug@protein complexation, the first step involved in a
number of hypersensitivity reactions, by a combination of fluorescence,
femtosecond transient absorption spectroscopy and molecular dynamics (MD)
simulations. Following this approach, the behavior of LAP and its metabolites has
been investigated in the presence of serum proteins, such as albumins and α1-acid
glycoproteins (SAs and AGs, respectively) from human and bovine origin. Fluorescence
results pointed to a higher affinity of LAP and its metabolites to human proteins; the
highest one was found for LAP@HSA. This is associated to the coplanar orientation
adopted by the furan and quinazoline rings of LAP, which favors emission from long-
lived (up to the ns time-scale) locally-excited (LE) states, disfavoring population of
intramolecular charge transfer (ICT) states. Moreover, the highly constrained
environment provided by subdomain IB of HSA resulted in a frozen conformation of
the ligand, contributing to fluorescence enhancement. Computational studies were
clearly in line with the experimental observations, providing valuable insight into the
nature of the binding sites and the conformational arrangement of the ligands inside the
protein cavities. Besides, a good correlation was found between the calculated binding
energies for each ligand@protein complex and the relative affinities observed in
competition experiments.
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INTRODUCTION
The human epidermal growth factor receptor (HER) family is
composed of four different members that have been thoroughly
investigated due to their important role in cancer progression.
HER receptors are transmembrane proteins that control a variety
of cell functions such as cell differentiation, proliferation,
apoptosis, migration and angiogenesis (Nicholson et al., 2001;
Hynes and Lane, 2005; Thomas and Weihua, 2019). However,
pathological alterations including overexpression or mutations in
the tyrosine-kinase site to HER-1 and/or HER-2 are directly
associated with the development of different types of human
cancer (Hynes and Lane, 2005; González and Lage, 2007; Ross
et al., 2016; Sigismund et al., 2018; Thomas and Weihua, 2019).
Lapatinib (LAP) is an orally administered drug that strongly
inhibits HER-1 and HER-2. It is generally used to treat breast
cancer, but due to its dual HER targeting it is expected to exhibit
higher activity than monotargeted tyrosine-kinase inhibitors; in
addition, its relatively small size allows LAP to cross the blood-
brain barrier, evidencing antitumor activity against brain
metastases (Lin et al., 2008; Lin et al., 2009; Johnston et al.,
2017). The LAP mechanism of action involves reversible binding
to the adenosine triphosphate site, stopping cellular growth and
proliferation, which results in enhanced apoptosis (Spector et al.,
2005; Schroeder et al., 2014). Furthermore, LAP undergoes
extensive biotransformation in humans leading to a number of
metabolites, including N- and O-dealkylated products (N-LAP
and O-LAP, respectively; see Figure 1) (Medina and Goodin,
2008; Towles et al., 2016).
Lapatinib gives rise to T cell-mediated hypersensitivity
reactions in the skin explant assay (Ahmed et al., 2019).
Moreover, dermatological adverse events including
papulopustular rash, pruritus, xerosis, and nail abnormalities
have been reported with LAP, similar to those described for
many other TKIs (Friedman et al., 2016). Generally,
hypersensitivity reactions occur when a drug (acting as a
hapten) has the ability to trigger an immune response. This
can be accomplished by different pathways, including
noncovalent interactions of drugs with immune receptors or
covalent binding of drugs to a protein, producing hapten-
protein conjugates, which can induce an immune response. It
is noteworthy that sometimes the drug itself does not participate
in the key event but instead a reactive metabolite or a
photoactivated species becomes covalently bound to the
protein and generates the allergic process (Nuin et al., 2016;
Limones-Herrero et al., 2020). In this context, photoallergic
reactions are related to immunological mechanisms, in which
the photoactivated drug (photosensitizer) is the key chemical
entity capable to interact with proteins (Andreu et al., 2010).
Indeed, it has recently been demonstrated that LAP and N-LAP
are able to induce phototoxicity and photogenotoxicity to cells,
while O-LAP did not display any photosensitized damage.
Besides, the parent drug showed higher activity in membrane
phototoxicity and protein oxidation than N-LAP (García-Lainez
et al., 2020).
Interestingly, LAP is known to bind to blood proteins
(>99%), mainly serum albumins (SAs) and α1-acid
glycoproteins (AGs) (Medina and Goodin, 2008). The
binding of drugs to transport proteins, such as SAs and AGs,
attracts increasing attention because key properties such as drug
function, pharmacokinetics, toxicity and transport to the target
cells are strongly modulated through drug@protein
complexation (Krasner, 1972; Peters, 1995). Moreover,
exposure of these complexes to sunlight may result in
photosensitivity disorders mainly associated with
phototoxicity and photoallergy (Vargas et al., 1993; Miranda
et al., 1994; Quintero and Miranda, 2000; Cosa, 2004;
Montanaro et al., 2009; Nuin et al., 2016; Vayá et al., 2016;
Blakely et al., 2019). In this context, it is known that drugs
containing the quinazoline moiety (the core chromophore of
LAP) can induce skin diseases such as allergic photodermatitis
(Ishikawa et al., 1994; Selvam and Kumar, 2011).
FIGURE 1 | Chemical structures of lapatinib (LAP) and its main metabolites N-LAP and O-LAP.
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Fluorescence and transient absorption spectroscopies are
useful techniques to investigate drug/protein interactions. This
is because excited state properties of drugs are very sensitive to the
microenvironment; thus, the yield of transients formation, as well
as their spectral profile and kinetic evolution, may be strongly
affected by the surroundings of the investigated chromophore
(Vayá et al., 2014). In particular, fluorescence and femtosecond
transient absorption are highly sensitive techniques that may
provide key information on the structural and dynamic features
of drug@protein complexation, revealing the nature of the early
primary processes occurring from the excited states in a time
window from the fs to the ns range, such as intersystem crossing,
energy/electron transfer or charge separation. In a parallel
approach, molecular dynamics (MD) simulations can be used
to study drug@biomolecule interactions (Spitaleri and Rocchia,
2019). Thus, properties such as the strength of interaction and the
conformational orientation of a drug in the neighborhood of the
amino acid residues of the protein binding sites can be
investigated in detail (Pérez-Ruiz et al., 2017; Pinheiro and
Curutchet, 2017; Molins-Molina et al., 2019; Spitaleri and
Rocchia, 2019).
In this framework, preliminary findings on LAP@SA
complexation point to a moderate binding of the drug in the
so-called site III (subdomain IB) of the protein (Shen et al., 2015;
Wilson et al., 2015; Kabir et al., 2016). In addition, a recent
photophysical study on the interactions between LAP, N-LAP or
O-LAP and HSA (Vayá et al., 2020) has shown that within the
constrained environment provided by the HSA cavities emission
occurs from long-lived locally excited (LE) states, whereas in the
bulk solution shorter-lived (70–90 ps) intramolecular charge
transfer (ICT) states predominate. This is related to the
relative conformational orientation of the furan vs. the
quinazoline ring in the different media.
With this background, the aim of the present work is to obtain
relevant information about the complexation of LAP and its N-
and O-dealkylated metabolites with serum proteins (SAs and
AGs) from human and bovine origin, as a model for the first step
involved in (photo)sensitivity reactions. To this end, a
combination of photophysical techniques (fluorescence and
femtosecond transient absorption spectroscopies) with MD
simulation studies has been employed. The obtained results
are relevant in connection with the capability of LAP to elicit




Lapatinib (CAS 231277-92-2), serum albumins and α1-acid
glycoproteins, from human and bovine origin, were purchased
from Sigma-Aldrich (Madrid, Spain). N-De[2-(methylsulfonyl)
ethyl lapatinib (N-LAP, CAS 697299-82-4) and O-De(3-
fluorobenzyl) lapatinib ditosylate salt (O-LAP; CAS 1268997-
70-1) were provided by Santa Cruz Biotechnology (Dallas, United
States) and Toronto Research Chemicals (North York, Canada),
respectively. PBS buffer was prepared by dissolving phosphate-
buffered saline tablets (Sigma-Aldrich) using ultrapure water
from a Millipore (Milli-Q Synthesis) system.
Spectroscopic Measurements
Steady-state absorption spectra were recorded in a JASCO V-760
spectrophotometer. Steady-state fluorescence spectra were
obtained using a JASCO-8500 spectrofluorometer system
provided with a monochromator in the wavelength range
200–900 nm, with an excitation wavelength of 295 or 340 nm
at 25°C. Measurements on drug or metabolite@protein complexes
were performed in aerated PBS of 1:1 M ratio mixtures at 5 μM.
Competing interactions were evaluated for solutions containing
LAP (or its metabolites) within a mixture of proteins in a 1:1:1 M
ratio (each component at 5 μM).
Time-resolved fluorescence measurements were done using an
EasyLife X system containing a sample compartment composed
of an automated Peltier cuvette holder to control the temperature,
a pulsed LED excitation source and a lifetime detector. The
employed LED excitation source was 340 nm, with emission
filter of GG400.
The UV and fluorescence measurements were recorded using
10 × 10 mm2 quartz cells at 25°C. The absorbance of the samples
at the excitation wavelength was kept below 0.1.
Femtosecond transient absorption experiments were
performed using a typical pump-probe system. The
femtosecond pulses were generated with a mode-locked Ti-
Sapphire laser of a compact Libra HE (4W power at 4 kHz)
regenerative amplifier delivering 100 fs pulses at 800 nm (1 mJ/
pulse). The output of the laser was split into two parts to generate
the pump and the probe beams. Thus, tunable femtosecond pump
pulses were obtained by directing the 800 nm light into an optical
parametric amplifier. In the present case, the pump was set at
330 nm and passed through a chopper prior to focus onto a
rotating cell (1 mm optical path) containing the samples in
organic or aqueous solution. The white light used as probe
was produced after part of the 800 nm light from the amplifier
traveled through a computer controlled 8 ns variable optical delay
line and impinge on a CaF2 rotating crystal. This white light was
in turn split in two identical portions to generate reference and
probe beams that then were focused on the rotating cell
containing the sample. The pump and the probe were made to
coincide to interrogate the sample. The power of the pump beam
was set to 180 μW. A computer-controlled imaging spectrometer
was placed after this path to measure the probe and the reference
pulses to obtain the transient absorption decays/spectra. The
experimental data were treated and compensated by the chirp
using the ExciPro program.
Molecular Docking
These calculations were performed using GOLD 5.8.1 program
(CCDC, 2020) and the protein coordinates were taken from: 1)
the crystal structure of HSA in complex with hemin and myristic
acid (PDB entry 1O9X) (Zunszain et al., 2003); 2) the crystal
structure of BSA in complex with 3,5-diiodosalicylic acid (PDB
entry 4JK4, chain A) (Sekula et al., 2013); 3) the crystal structure
of HAG in the unbound form (PDB entry 3KQ0) (Schonfeld et al.,
2008); and 4) our previously reported homology model of BAG
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using the Phyre2 (Kelley et al., 2015) homology modeling web
server (Limones-Herrero et al., 2017). The experimental procedure
was similar to that described for: 1) 2-acetoxy-4-
trifluoromethylbenzoic acid (triflusal) (Molins-Molina et al.,
2019) and HSA protein with the exception that the position of
heminwas used to define the binding pocket, and the radius was set
to 10 Å; and 2) carprofen methyl ester and the homology model of
BSA (Limones-Herrero et al., 2017). The protonated forms of the
ligands (secondary and primary amines) were employed.
Molecular Dynamics Simulation Studies
The highest score solution obtained by docking was subjected to
100 ns of dynamic simulation. The experimental protocol
involved: 1) the minimization of the ligands (LAP, N-LAP and
O-LAP); 2) the generation and minimization of the binary LAP@
protein, N-LAP@protein, and O-LAP@protein complexes
(protein  HSA, BSA, HAG, and BAG) using the poses
obtained by docking; and 3) MD simulations of the resulting
minimized ligand@protein complexes. The protocol was
performed as described for triflusal and carprofen methyl ester
(Limones-Herrero et al., 2017; Molins-Molina et al., 2019). The
analysis of the trajectories and the rmsd of the atomic positions of
the protein and the ligands during the simulation were analyzed
by using the cpptraj module in AMBER 16 (Case et al., 2016). The
binding free energies of LAP in the LAP@HSA and LAP@BSA
complexes were calculated using the MM/PBSA (Miller et al.,
2012) approach in explicit water (generalized Born, GB) as
implemented in Amber. The protein figures disclosed were
created by using the molecular graphics program PyMOL
(DeLano, 2020). For figures related to HSA, BSA and HAG
proteins, the amino acid numbering described in PDB entries
1O9X, 4JK4, and 3KQ0, respectively, was employed. For figures
related to BAG protein, the numbering of the protein sequence
was used.
RESULTS AND DISCUSSION
The photobehavior of LAP and its metabolites was investigated in
aqueous buffer solution and in the presence of an equimolar
amount of protein. For this purpose, two types of transport
proteins were selected: serum albumins and α1-acid
glycoproteins from human (HSA and HAG) and bovine (BSA
and BAG) origin, respectively. As previously observed, LAP and
N-LAP formed aggregates in PBS solution (Wilson et al., 2015;
Vayá et al., 2020); however, upon interaction with proteins they
were completely solubilized. The UV absorption spectra of LAP,
N-LAP and O-LAP bound to HSA, BSA, HAG and BAG did not
reveal significant differences (Supplementary Figure S1).
Emission of the protein-bound LAP (or metabolites) was first
investigated at λexc  295 nm, where both the protein and the drug
absorb light. In PBS, the fluorescence of LAP was weak and
unstructured (λmax ∼ 475 nm) due to aggregation but most
importantly due to emission from intramolecular charge
transfer (ICT) states, which are favored in a twisted
orientation between the furan and quinazoline rings due to the
freedom in the degrees of movement of the drug in solution (Vayá
et al., 2020). However, in the presence of protein, which provides
a more constrained environment, a clear enhancement of LAP
fluorescence in addition to quenching of the protein emission
(λmax ∼ 340 nm) was noticed (see Supplementary Figure S2).
This effect was previously detected for the drug complexed to
HSA, and was associated to singlet-singlet energy transfer (SSET)
from HSA to LAP (Vayá et al., 2020). On the other hand, the
spectra within each protein were unstructured and displayed their
maxima at shorter wavelengths (ca. 450 nm) compared to the free
drug in PBS. Quenching of the protein fluorescence (λmax ∼
340 nm) upon interaction with LAP, N-LAP and O-LAP was
different for each complex (Supplementary Figures S2–S4;
Supplementary Table S1). In general, higher quenching due
to SSET was detected for the human proteins; besides, SAs
appeared to induce greater deactivation than AGs. This can be
associated to the encapsulation of the drug (or metabolite) inside
the protein, which was stronger for LAP@protein compared to
N-LAP and O-LAP.
More relevant from the photobiological point of view was the
emission behavior of LAP and its metabolites upon excitation
with UVA light (λexc  340 nm), as this type of radiation is
selectively absorbed by the drug chromophore and does not
interact directly with biomolecules. The obtained results for
LAP, N-LAP and O-LAP, upon excitation at 340 nm are
shown in Figure 2.
In contrast to the strong and structured fluorescence with
maxima at ca. 425 nm detected for LAP and N-LAP within HSA
(Figures 2A,B), the emissions of the other ligand@protein
complexes were much weaker and unstructured, and the
maxima were found at longer wavelengths (∼450 nm). The
behavior within HSA was associated to the more constrained
environment provided by the protein but also to the frozen
coplanar orientation adopted by the furan and quinazoline
rings of LAP or N-LAP, which favors emission from LE
(locally excited) states (Vayá et al., 2020). On the contrary,
binding to BSA, HAG or BAG might disfavor emission from
LE states due to a certain degree of freedom for twisting between
both rings, resulting in a diminished and red-shifted emission of
the encapsulated LAP or N-LAP. This would imply that the
confinement and the conformational arrangement of the ligands
within the protein cavities are key factors controlling the
photobehavior. As regards the fluorescence lifetimes, decay
kinetics were measured upon excitation at 340 nm
(Supplementary Figure S5). In general, shorter lifetimes
(<1 ns) were determined for LAP and N-LAP bound to AGs
than those determined within SAs, which ranged from 1 to 1.5 ns
(Supplementary Table S2). Besides, the decay traces were faster
for N-LAP than for the parent drug, which is in line with the
steady-state results. Again, little if any emission was detected for
O-LAP in the presence of the different proteins, suggesting the
feasibility of alternative deactivation pathways, for instance
excited state deprotonation of the phenol moiety.
Furthermore, both SAs and AGs are transport proteins present
in the plasma. Under normal conditions, the concentration of the
former is higher; however, this situation may change significantly
under a variety of conditions (for instance, during inflammatory
processes), where AGs can play a significant role (Kremer et al.,
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1988; Bteich, 2019). Thus, it makes sense to investigate competing
interactions of LAP or N-LAP with SAs and AGs in protein
mixtures, upon selective excitation of the drug chromophore, to
check the relative affinities to both types of proteins.
As it is shown in Figure 3, the emission spectra of LAP@
HSA+HAG upon excitation at 340 nm was intermediate between
the LAP@HSA and the LAP@HAG profiles; however, the shape
and position of the band was more similar to that of LAP@HSA.
A similar trend was also detected for LAP in a mixture of BSA and
BAG, where LAP preferentially binds to BSA. Competing
interactions of LAP in mixtures containing other protein
combinations are shown in Supplementary Figure S6. Thus,
it can be concluded that LAP interacts more strongly with the
human proteins than with those of bovine origin; the weakest
interaction was evidenced for BAG. A similar behavior was
revealed for N-LAP in a mixture of proteins, as it can be
deduced from the emission spectra shown in Supplementary
Figure S7.
In order to get a deeper insight into the nature of LAP-protein
binding, the photobehavior of the complexes was examined in the
very early stages after exposure to UVA light, by means of
femtosecond transient absorption measurements, upon
excitation at 330 nm. The spectral shapes of the species
detected for LAP in its complexes with BSA, HAG and BAG
(Supplementary Figure S8) were in good accordance with that
obtained previously for LAP@HSA (Vayá et al., 2020). Thus, a
transient absorption band with relative maxima at ca. 425 and
530 nmwas observed for LAP@BSA; similar profiles were noticed
for LAP@AGs, with maxima around 425 and 550 nm. These
transients were assigned to the LE singlet-singlet absorption
species; their kinetic traces decayed double-exponentially
(Figure 4). Thus, for SAs, short components with lifetimes of
ca. 12 ps were evidenced, while the longer components were
species-dependent and decayed faster for BSA than for HSA,
reaching the ns time-scale. For the AGs, the short components
decayed with lifetimes around 6 ps while the long ones survived
until the ns time-scale. The two lifetime components could be
associated to the LE states of LAP within the constrained
environment provided by the protein; the short components
would arise from the reorganization of the drug in the initial
steps after excitation, whereas the long ones would correspond to
the stabilized conformation within the protein cavities. Actually,
the signature of ICT states was not evidenced in any of the LAP@
protein complexes.
FIGURE 2 | Fluorescence spectra at λexc  340 nm for (A) LAP@HSA (solid black), LAP@BSA (solid red), LAP@HAG (dashed black) and LAP@BAG (dashed red);
(B) N-LAP@HSA (solid black), N-LAP@BSA (solid red), N-LAP@HAG (dashed black) and N-LAP@BAG (dashed red); (C) O-LAP@HSA (solid black), O-LAP@BSA (solid
red), O-LAP@HAG (dashed black) and O-LAP@BAG (dashed red). All mixtures were at 1:1 M ratio (5 μM) in PBS under air, using isoabsorptive solutions at the excitation
wavelength. The inset in (C) shows a zoom of the low emissive states for the O-LAP@protein complexes.
FIGURE 3 | Fluorescence spectra at λexc  340 nm for (A) LAP@HSA (solid black), LAP@HAG (dashed black) and LAP@HSA+HAG (solid blue), and (B) LAP@BSA
(solid red), LAP@BAG (dashed red) and LAP@BSA+BAG (solid blue). For LAP@protein, solutions of 1:1 M ratio (5 μM) were prepared, while for LAP@protein1+protein2,
solutions of 1:1:1 M ratio (5 μM) were used.
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In order to understand the marked experimental differences in
the photobehavior of LAP and its metabolites interacting with
SAs and AGs, the binding mode was investigated by
computational studies. This was first analyzed by molecular
docking using the program GOLD, version 5.8.1, and further
validated by MD simulation studies.
For SAs, the ligands LAP, N-LAP and O-LAP were docked to
subdomain IB. Experimental evidence to assign subdomain IB as
the preferred binding site in HSA was previously obtained using
selective site I and site II probes such as warfarin (WRF) and
ibuprofen (IBP), respectively (Vayá et al., 2020). The resulting
ligand@protein binary complexes were submerged in a truncated
octahedron of water molecules and further analyzed by MD
simulations (100 ns) using the molecular mechanics force field
AMBER to achieve reliable models (Götz et al., 2012; Le Grand
et al., 2013; Salomon-Ferrer et al., 2013). All ligand@protein
FIGURE 4 | Femtosecond transient absorption decays for (A) LAP@HSA (black) and LAP@BSA (red) monitored at 530 nm, and for (B) LAP@HAG (black) and
LAP@BAG (red) monitored at 550 nm, in PBS after excitation at 330 nm.
FIGURE 5 |Overall view of the proposed binding modes of LAP (pink), N-LAP (orange) and O-LAP (yellow) to HSA (magenta, A,B) and BSA (blue,C,D) as obtained
by MD simulation studies. (A,C) Superposition of the binding modes of the three ligands to subdomain IB of HSA (A) and BSA (C). (B,D) Detailed views of the proposed
binary ligand@HSA (B), and ligand@BSA (D) complexes.
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complexes proved to be very stable during simulation, as
evidenced by the low values of the root-mean-square deviation
(rmsd) for the whole protein backbone (Cα, C, N and O atoms)
calculated for all complexes (average values range from 0.7 to
2.0 Å) (Supplementary Figures S9–S12).
The results of the MD simulation studies carried out for the
ligand@SA complexes revealed that: 1) all ligands displayed a
more deeply embedded arrangement in subdomain IB when
bound to HSA than to BSA; 2) for the BSA complexes, a
portion of the ligands was exposed to the solvent
environment, particularly in the case of LAP. Specifically, the
overall arrangement adopted by LAP or N-LAP was found to be
clearly different in HSA compared to BSA (Figure 5). Thus, for
LAP@BSA only part of the ligand interacted within the protein
binding site, while N-LAP was rotated 180° within BSA to locate
the ammonium moiety in close contact with the solvent. In any
case, all ligands would be stabilized by numerous apolar
interactions with the side chain residues within subdomain IB,
as well as hydrogen bonding interactions through the ammonium
group and the nitrogen atoms of the quinazoline ring. In addition,
conformational analysis of the ligands within subdomain IB
showed that: 1) only LAP and O-LAP would achieve an
almost coplanar arrangement of the furyl and quinazoline
rings upon binding to HSA, showing average dihedral angles
FIGURE 6 | Interactions of LAP (pink, A,D), N-LAP (orange, B,E), and O-LAP (yellow,C,F) to HSA (gray, A–C) and BSA (green,D–F) as obtained by MD simulation
studies. Snapshots after 80 ns are shown. Relevant side chain residues are shown (lines) and labeled. Ligands are indicated as sticks. Hydrogen bonding interactions
between the ligands and the protein are shown as blue dashed lines. (G) Variation of the dihedral angle between the furyl and quinazoline rings for LAP bound to HSA or
BSA during the whole simulation. The bonds involved in the dihedral angle are highlighted in pink.
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of 8.3° and 7.3°, respectively, being their relative conformations
frozen within the pocket; 2) on the contrary, free rotation around
the linkage of the furyl and quinazoline rings was possible for
LAP@BSA, O-LAP@BSA and the two N-LAP@SA complexes
(Figure 6; Supplementary Figure S13).
Unlike SAs that can undergo large conformational changes
upon binding a variety of ligands, specifically in domains I and III
(Curry et al., 1998; Pérez-Ruiz et al., 2017), the plasticity of AGs is
intrinsically more limited. Their central motif, which is composed
by an eight-stranded β-barrel and is flanked by an α-helix, makes
them constrained receptacles for ligand recognition. It is
therefore not surprising that the MD simulation studies
carried out for the ligand@AG complexes showed that the
overall flexibility of LAP or its metabolites within the binding
pockets would be restricted to some extent (Figures 7A–C;
Supplementary Figure S14). This effect was found to be more
pronounced for the ligand@HAG complexes, where the drug and
its metabolites would be well surrounded by the protein. In
addition, a similar arrangement of LAP, N-LAP and O-LAP
within HAG was observed, with an almost coplanar
arrangement of the furyl and quinazoline rings (Figure 7D;
Supplementary Figure S15). However, although this effect
would favor emission from LE states, the weaker intensity
observed for HAG compared to HSA could be associated with
the larger binding site of the former (Supplementary Figure
S16), which may reduce the matrix effect provided by the protein
cavities. On the contrary, for ligand@BAG it can be summarized
that: 1) no common pattern of recognition was identified; 2) more
solvent-exposed complexes were obtained; and 3) no coplanarity
between the aromatic moieties was observed (Figures 7E–H;
Supplementary Figures S14 and S15). In general, the MD
simulation results are in line with the experimental data, as
they justify the higher emission of LAP bound to HSA
compared with the other proteins, in addition to the stronger
affinity to the human proteins, as a result of the deeper embedded
arrangement with higher restriction in the degrees of movement
compared to the bovine proteins. Besides, the stronger emission
of N-LAPwithin HSA and the weaker emission of the drug and its
metabolites in BAG are also explained.
Finally, the binding free energies of LAP, N-LAP and O-LAP
interacting with the investigated proteins (HSA, BSA, HAG and
BAG) in the corresponding ligand@protein complex were
calculated using the MM/PBSA approach (Miller et al., 2012)
FIGURE 7 | Overall view of the proposed binding modes of LAP (pink, A,E), N-LAP (orange, B,F) and O-LAP (yellow, C,G) to HAG (gray) and BAG (green) as
obtained by MD simulation studies. (D,H) Superposition of the binding modes of the tree ligands in the recognition pocket of HAG (D) and BAG (H). Note how the furyl
and quinazoline rings of the ligands for the HAG complexes would be almost coplanar and all ligands would show a similar arrangement.
TABLE 1 | Calculated binding free energies using MM/PBSA.a
Ligand Protein Complex Energy
LAP HSA LAP@HSA −56.7 ± 0.2b
— BSA LAP@BSA −36.2 ± 0.3b
— HAG LAP@HAG −54.3 ± 0.3b
— BAG LAP@BAG −50.4 ± 0.4b
N-LAP HSA N-LAP@HSA −43.5 ± 0.2b
— BSA N-LAP@BSA −35.3 ± 0.2b
— HAG N-LAP@HAG −39.1 ± 0.2b
— BAG N-LAP@BAG −40.2 ± 0.3b
O-LAP HSA O-LAP@HSA −37.2 ± 0.2b
— BSA O-LAP@BSA −35.9 ± 0.2b
— HAG O-LAP@HAG −41.3 ± 0.2b
— BAG O-LAP@BAG −34.0 ± 0.2b
aEnergy units  kcal mol−1.
bStandard error of mean.
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in explicit water (generalized Born, GB) as implemented in
Amber (Table 1). These energies were estimated by
subtracting the free energy of the corresponding unbound
components, i.e. ligand and protein, to the free energy of the
ligand@protein complex. The results revealed that the binding
affinity of LAP to the human proteins is higher than to the bovine
ones, especially in the case of SAs. Thus, LAP would have a 1.6-
fold higher affinity for HSA than for BSA. This is mainly caused
by the distinct amino acid sequence of the subdomain IB for both
SAs (Supplementary Figure S17). These differences in the
intraprotein microenvironments that surround the ligands are
responsible for the type and strength of the stabilization
interactions, as it can be observed from Figures 6A–F. This
effect is even greater when comparing SAs and AGs in which the
ligand-binding pockets are markedly different, either in amino
acid sequence (Supplementary Figure S18) as well as in their
tridimensional arrangement. In addition, the affinity of both
metabolites to the investigated proteins was found to be
weaker than that of the parent drug, following the order LAP
>> N-LAP > O-LAP. Again, these results are qualitatively in line
with those obtained from the fluorescence measurements, where
higher affinity of either LAP or its metabolites was found for the
human proteins, with the highest one observed for LAP@HSA.
CONCLUSION
The interaction of Lapatinib (LAP) and its N- and
O-dealkylated metabolites (N-LAP and O-LAP) with model
proteins (serum albumins and α1-acid glycoproteins, SAs and
AGs), of human and bovine origin, has been investigated by a
combined photophysical and computational approach. In this
context, the present work reveals key information on drug@
protein complexation, the first step involved in a number of
hypersensitivity reactions, including photosensitivity disorders.
Photophysical results (fluorescence and ultrafast transient
absorption) agree with strong and specific interactions of the
drug and its metabolites with the selected proteins, pointing to a
higher affinity to the human proteins, especially in the case of
the LAP@HSA complex. The observed behavior can be
rationalized by the coplanar orientation adopted by the furan
and quinazoline rings within subdomain IB of HSA, in
conjunction with the degree of confinement provided by this
constrained intraprotein microenvironment. The experimental
findings can be undoubtedly explained by the MD simulation
studies. Thus, the weaker emission observed within BSA is
explained by the higher exposure of part of the ligand to the
bulk solution and also by the conformational arrangements and
the degrees of freedom within the BSA binding site. Finally, the
calculated binding energies for ligand@protein complexes are
also in line with the relative affinities found in the competition
experiments.
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